Abbisko

Abbisko is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and differentiated small-molecule oncology therapies. Since its establishment in 2016, the company has strategically designed and developed a pipeline of 14 oncology-focused drug candidates, including five candidates in clinical stages. The company’s product candidates mainly focus on small molecules in the fields of precision oncology treatment and small-molecule cancer immunotherapy.The company has two core product candidates, ABSK011 and ABSK091, along with 12 other pipeline candidates. ABSK011, independently developed, is an effective and highly selective small-molecule fibroblast growth factor receptor 4 (FGFR4) inhibitor. ABSK091 (licensed from AZ, formerly known as AZD4547) is a molecularly targeted candidate that acts as a potent and selective inhibitor of FGFR subtypes 1, 2, and 3. At this stage, the company’s core product candidates are primarily being developed for HCC, UC, and GC.